Supplementary Table S3. Top 10 up-regulated and down-regulated genes in samples Top 10 up-regulated genes

Gene log2(Fold-change) p-value Role in based on literature Refs Symbol and database search PLA2G2A 2.3884419 0 An enzyme in inflammatory process, might [1] serve as a prognostic marker ORM1 3.9940791 0 AR-activated gene and involved in AR [2, 3] pathway TARP 2.0779529 3.13E-196 Prostate-specific protein and leads to [4, 5] increased growth rate of prostate cancer cells ORM2 3.0434879 1.52E-157

PCA3 4.0035279 1.26E-132 Highly expressed in prostate cancer tissue, a [5, 6] genetic marker for prostate cancer diagnosis SPON2 2.0706815 9.75E-121 Over expressed in prostate cancer tissues, [7] could be used as a HPN 2.4321643 5.79E-49 Involved in maintenance of cell morphology [8] and growth of various cancer types, correlates with progression of prostate cancer and promotes cancer progression and metastasis STEAP4 1.9395011 4.48E-44 Module metastasis and invasion of cancer [9] cells through regulating focal adhesion kinase activation MCCC2 2.0394019 4.89E-41 AR-regulated gene and strongly up-regulated [10] in primary prostate cancer PDLIM5 1.8980125 2.39E-40

Top 10 down-regulated genes

Gene log2(Fold-change) p-value Role in prostate cancer based on literature Refs Symbol and database search SERPINA3 -1.496602 0 Associated with increased risk of prostate [11] cancer LTF -1.576865 0 Plays roles in several important biological [12, 13] processes such as cellular growth, inflammatory response, cancer development and metastasis SAA1 -4.021895 0

LCN2 -2.156207 0

SOD2 -0.886676 1.82E-268 A tumor suppressor gene, the suppression of [14] prostate cancer cell growth by mediating the senescence-associated tumor suppression CFB -1.251122 5.91E-225

MT2A -0.516269 2.57E-188 Interact with kinase domain of protein kinase [15] Cmu(PKCmu) in prostate cancer OLFM4 -1.481793 6.63E-188 Inhibit prostate cancer growth and metastasis [16] with interaction of and SDF-1 PSCA -0.367134 1.70E-186

S100A9 -2.169907 8.63E-143

References

1. Mirtti T, Laine VJ, Hiekkanen H, Hurme S, Rowe O, Nevalainen TJ, Kallajoki M, Alanen K: Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality. Apmis 2009, 117(3):151-161. 2. Whitworth H, Bhadel S, Ivey M, Conaway M, Spencer A, Hernan R, Holemon H, Gioeli D: Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen. PLoS One 2012, 7(6):e38950. 3. Erg U N A, Lawrence CA, Kohanski MA, Brennan TA, Collins JJ: A network biology approach to prostate cancer. Molecular systems biology 2007, 3(1). 4. Wolfgang CD, Essand M, Vincent JJ, Lee B, Pastan I: TARP: a nuclear protein expressed in prostate and cells derived from an alternate reading frame of the T cell receptor gamma chain locus. Proc Natl Acad Sci U S A 2000, 97(17):9437-9442. 5. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB: DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999, 59(23):5975-5979. 6. Loeb S: Does PCA3 help identify clinically significant prostate cancer? Eur Urol 2008, 54(5):980-981. 7. Qian X, Li C, Pang B, Xue M, Wang J, Zhou J: Spondin-2 (SPON2), a more prostate-cancer- specific diagnostic biomarker. PLoS One 2012, 7(5):e37225. 8. Pace G, Pomante R, Vicentini C: Hepsin in the diagnosis of prostate cancer. Minerva Urol Nefrol 2012, 64(2):143-148. 9. Tamura T, Chiba J: STEAP4 regulates focal adhesion kinase activation and CpG motifs within STEAP4 promoter region are frequently methylated in DU145, human androgen-independent prostate cancer cells. Int J Mol Med 2009, 24(5):599-604. 10. Marques RB, Dits NF, Erkens-Schulze S, van Ijcken WF, van Weerden WM, Jenster G: Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines. PLoS One 2011, 6(8):e23144. 11. Licastro F, Bertaccini A, Porcellini E, Chiappelli M, Pernetti R, Sanguedolce F, Marchiori D, Martorana G: Alpha 1 antichymotrypsin genotype is associated with increased risk of prostate and PSA levels. Anticancer Res 2008, 28(1B):395-399. 12. Rodrigues L, Teixeira J, Schmitt F, Paulsson M, Mansson HL: Lactoferrin and cancer disease prevention. Crit Rev Food Sci Nutr 2009, 49(3):203-217. 13. Shaheduzzaman S, Vishwanath A, Furusato B, Cullen J, Chen Y, Banez L, Nau M, Ravindranath L, Kim KH, Mohammed A et al: Silencing of Lactotransferrin expression by methylation in prostate cancer progression. Cancer Biol Ther 2007, 6(7):1088-1095. 14. Plymate SR, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Zhang Y, Oberley LW, Zhong W, Drivdahl R, Oberley TD: Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein- related protein-1. Oncogene 2003, 22(7):1024-1034. 15. Rao PS, Jaggi M, Smith DJ, Hemstreet GP, Balaji KC: Metallothionein 2A interacts with the kinase domain of PKC$\mu$ in prostate cancer. Biochem Bioph Res Co 2003, 310(3):1032-1038. 16. Chen L, Li H, Liu W, Zhu J, Zhao X, Wright E, Cao L, Ding I, Rodgers GP: Olfactomedin 4 suppresses prostate cancer cell growth and metastasis via negative interaction with cathepsin D and SDF-1. Carcinogenesis 2011, 32(7):986-994.